Controversies in the Treatment of Lung Cancer

Description

Under the auspices of the 12th International Symposium on Special Aspects in Radiotherapy 2008 in Berlin, acknowledged experts presented their perspectives on small and non-small cell lung cancer, reflecting the latest standards and engaging in controversies in the diagnosis and treatment of this disease.

Informations

• Publié par: S. Karger AG
• Date de parution: 07 décembre 2009
• Nombre de lectures: 0
• EAN13: 9783805592994
• Langue: English
• Poids de l'ouvrage: 3 Mo

Extrait

Controversies in the Treatment of Lung Cancer
Frontiers of Radiation Therapy and Oncology
Vol. 42
Series Editors
J.L. Meyer     San Francisco, Calif.
W. Hinkelbein     Berlin
 
12th International Symposium on Special Aspects of Radiotherapy Berlin, October 3-4, 2008
Controversies in the Treatment of Lung Cancer
Volume Editors
J. Heide     Berlin
A. Schmittel     Berlin
D. Kaiser     Berlin
W. Hinkelbein     Berlin
34 figures, 4 in color, and 27 tables, 2010
Frontiers of Radiation Therapy and Oncology
Founded 1968 by J.M. Vaeth, San Francisco, Calif.
_________________________
_________________________
Dr. Jürgen Heide Department of Radiooncology and Radiotherapy Charité- Campus Benjamin Franklin Berlin, Germany
Prof. Dr. Dirk Kaiser Department of Thoracic Surgery Helios Klinikum Emil von Behring Chest Hospital Heckeshorn Berlin, Germany
_________________________
_________________________
PD Dr. Alexander Schmittel Department of Medical Oncology Charité- Campus Benjamin Franklin Berlin, Germany
Prof. Dr. Wolfgang Hinkelbein Department of Radiooncology and Radiotherapy Charité- Campus Benjamin Franklin Berlin, Germany
Library of Congress Cataloging-in-Publication Data
International Symposium on Special Aspects of Radiotherapy (12th: 2008: Berlin, Germany) Controversies in the treatment of lung cancer / 12th International
Symposium on Special Aspects of Radiotherapy, Berlin, October 3-4, 2008; volume editors, J. Heide .. [et al.].
p. ; cm. – (Frontiers of radiation therapy and oncology, ISSN 0071-9676; v. 42)
Includes bibliographical references and indexes.
ISBN 978-3-8055-9298-7 (hard cover: alk. paper)
1. Lungs – Cancer – Radiotherapy – Congresses. I. Heide, J. (Jürgen) II. Title. III. Series: Frontiers of radiation therapy and oncology, v. 42. 0071-9676;
[DNLM: 1. Lung Neoplasms-Radiotherapy-Congresses. 2. Lung Neoplasms- Surgery- Congresses. W3 FR935 v.42 2010 / WF 658 I612c 2010]
RC280.L8I58 2008
616.99’424–dc22
2009038886
Bibliographic Indices. This publication is listed in bibliographic services, including Current Contents ® and PubMed/MEDLINE.
Disclaimer. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the book is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Drug Dosage. The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
© Copyright 2010 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)
www.karger.com
Printed in Switzerland on acid-free and non-aging paper (ISO 9706) by Reinhardt Druck Basel
ISSN 0071-9676
ISBN 978-3-8055-9298-7
e-ISBN 978-3-8055-9299-4
 
Contents
Diagnostic Workup
_______________________
Prognostic Factors in Histopathology of Lung Cancer
Fisseler-Eckhoff, A. (Wiesbaden)
FDG-PET/CT in Lung Cancer: An Update
Baum, R.P.; Świętaszczyk, C.; Prasad, V. (Bad Berka)
Whole-Body Magnetic Resonance Imaging for Staging of Lung Cancer
Puls, R.; Kühn, J.-P.; Ewert, R.; Hosten, N. (Greifswald)
Bronchoscopy/Endobronchial Ultrasound
Herth, F.J.F. (Heidelberg)
New Developments in Videomediastinoscopy: Video-Assisted Mediastinoscopic Lymphadenectomy and Mediastinoscopic Ultrasound
Witte, B. (Koblenz)
NSCLC: Stage I/II Disease
_______________________
Resection in Stage I/II Non-Small Cell Lung Cancer
Smolle-Juettner, F.M.; Maier, A.; Lindenmann, J.; Matzi, V.; Neuböck, N. (Graz)
Role of Mediastinal Lymph Node Dissection in Non-Small Cell Lung Cancer
Bölükbas, S. (Wiesbaden); Eberlein, M.H. (Baltimore, Md.); Schirren, J. (Wiesbaden)
Radiation Therapy for Early Stage (I/II) Non-Small Cell Lung Cancer
Jeremic, B. (Vienna); Casas, F. (Barcelona); Wang, L. (Beijing); Perin, B. (Sremska Kamenica)
Stereotactic Body Radiation Therapy for Early Non-Small Cell Lung Cancer
Zimmermann, F. (Basel); Wulf, J. (Bern); Lax, I. (Stockholm); Nagata, Y. (Hiroshima); Timmerman, R.D. (Dallas, Tex.); Stojkovski, I.; Jeremic, B. (Vienna)
NSCLC: Stage III Disease
_______________________
Extended Surgical Resection in Stage III Non-Small Cell Lung Cancer
Hillinger, S.; Weder, W. (Zürich)
Stage III: Definitive Chemoradiotherapy
Fietkau, R.; Semrau, S. (Erlangen)
Adjuvant Therapy in Early-Stage Non-Small Cell Lung Cancer
Serke, M. (Hemer)
Postoperative Irradiation in Non-Small Cell Lung Cancer
Höcht, S. (Berlin/Hamburg); Heide, J. (Berlin); Bischoff, R.; Gründel, O.; Carstens, D. (Hamburg)
Altered Fractionation Schemes in Radiotherapy
Stuschke, M.; Pöttgen, C. (Essen)
NSCLC: Palliative Procedures in Stage IV
_______________________
Chemotherapy of Advanced Non-Small Cell Lung Cancer
Pirker, R.; Minar, W. (Vienna)
Radiotherapy
Adamietz, I.A. (Herne)
Small Cell Lung Cancer
_______________________
Treatment of Limited Disease Small Cell Lung Cancer
De Ruysscher, D. (Maastricht)
Radiochemotherapy in Extensive Disease Small Cell Lung Cancer ED-SCLC
Jeremic, B. (Vienna); Casas, F. (Barcelona); Wang, L. (Beijing); Perin, B. (Sremska Kamenica)
Radiotherapy for Extensive Stage Small Cell Lung Cancer
Slotman, B.J. (Amsterdam)
Controversies in the Treatment of Advanced Stages of Small Cell Lung Cancer
Schmittel, A. (Berlin)
Use of Complementary and Alternative Medicine in Lung Cancer
_______________________
Complementary and Alternative Medicine in Lung Cancer Patients: A Neglected Phenomenon?
Micke, O. (Bielefeld/Münster); Büntzel, J. (Nordhausen/Bielefeld); Kisters, K. (Herne/Bielefeld); Schäfer, U. (Lemgo/Bielefeld); Micke, P. (Uppsala); Mücke, R. (Lemgo/Bielefeld)
Author Index
Subject Index
Diagnostic Workup
Heide J, Schmittel A, Kaiser D, Hinkelbein W (eds): Controversies in the Treatment of Lung Cancer. Front Radiat Ther Oncol. Basel, Karger, 2010, vol 42, pp 1–14
______________________
Prognostic Factors in Histopathology of Lung Cancer
Annette Fisseler-Eckhoff
Institute of Pathology and Cytology, Dr. Horst-Schmidt Clinic, Wiesbaden, Germany
______________________
Abstract
Carcinoma of the lung is the most common cause of cancer-related death in men and women. Prognosis correlates strongly with stage of disease at presentation and to some degree with the histological subtype of the tumor. Histological classifications of lung cancer were somewhat arbitrary and a matter of convenience. However, multiple lines of differentiation are often found within a single tumor, if it is sufficiently sampled. The new therapeutic approaches especially of non-small cell lung cancer place high demands on pathologists: a clear histological diagnosis with information on the predominant histological subtype is required, obtained by using additional immunohistochemical methods. Using molecular methods, predictive and prognostic factors for adjuvant and neoadjuvant therapies can be identified in tumor cells of small cell lung cancer and non-small cell lung cancer. Biological and molecular factors known in this regard include the epidermal growth factor family and its receptors, K-RAS mutations, neuroendocrine tumor differentiation, and nucleotide-excision-repair proteins (ERCC1 and RRM1). Thymidilate synthase is an interesting target for anticancer agents such as the antifolate pemetrexed. Given the aspect of individualized lung cancer therapy, the collective term small cell/non-small cell lung cancer introduced by the groups of Chuang in 1984 and Thomas in 1993 can be regarded as no longer sufficient.
Copyright © 2010 S. Karger AG, Basel
Carcinoma of the lung is the leading cause of cancer-related death in both men and women. Concerning lung cancer incidence in five continents, it was demonstrated by Parkin et al. [ 1 ] that non-small cell lung cancer (NSCLC) accounts for almost 75% of cases, small cell carcinomas (SCC) comprise about 15% and large cell/undifferentiated carcinomas about 9%. Lung cancer is a dynamic and diverse disease associated with numerous somatic mutations, deletions, and amplification events. Pa